Skip to main content
SpringerLink
Log in

Comment on: ‘Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition’

  • Letter to the Editor
  • Published:
Applied Health Economics and Health Policy Aims and scope Submit manuscript

The Original Article was published on 02 December 2019

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Levaggi R, Pertile P. Value-based pricing alternatives for personalised drugs: implications of asymmetric information and competition. Appl Health Econ Health Policy. 2019. https://doi.org/10.1007/s40258-019-00541-z.

    Article  Google Scholar 

  2. Garattini L, Padula A. Precision medicine and monoclonal antibodies: breach of promise? Croat Med J. 2019;60(3):284–9.

    Article  CAS  Google Scholar 

  3. Garattini L, Padula A. Immunotherapies for advanced melanoma: as promising as they are expensive? J R Soc Med. 2017;110(10):395–9.

    Article  Google Scholar 

  4. van de Vooren K, Curto A, Garattini L. Optional copayments on anti-cancer drugs. BMJ. 2013;346:f349.

    Article  Google Scholar 

  5. van de Vooren K, Curto A, Garattini L. Biosimilar versus generic drugs: same but different? Appl Health Econ Health Policy. 2015;13(2):125–7.

    Article  Google Scholar 

  6. Garattini L, Padula A. Pharmaceutical pricing conundrum: time to get rid of it? Eur J Health Econ. 2018;19(8):1035–8.

    Article  Google Scholar 

  7. Garattini L, Padula A. Dutch guidelines for economic evaluation: ‘from good to better’ in theory but further away from pharmaceuticals in practice? J R Soc Med. 2017;110(3):98–103.

    Article  Google Scholar 

  8. Garattini L, Padula A. Competition in pharmaceuticals: more product- than price-oriented? Eur J Health Econ. 2018;19(1):1–4.

    Article  Google Scholar 

  9. Garattini L, Curto A, Freemantle N. Personalized medicine and economic evaluation in oncology: all theory and no practice? Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):733–8.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Health Economics, Institute for Pharmacological Research Mario Negri IRCCS, Ranica, Italy

    Livio Garattini

  2. Institute of Clinical Trials and Methodology, University College London, London, UK

    Nick Freemantle

Authors
  1. Livio Garattini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nick Freemantle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Livio Garattini.

Ethics declarations

Funding

No sources of funding were used to conduct this study or prepare this manuscript.

Conflict of interest

Nicholas Freemantle and Livio Garattini have no conflicts of interest directly relevant to this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garattini, L., Freemantle, N. Comment on: ‘Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition’. Appl Health Econ Health Policy 18, 453–454 (2020). https://doi.org/10.1007/s40258-020-00552-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40258-020-00552-1

Search

Navigation